(Am J Obstet Gynecol. 2017;216(3):204–205)
This editorial advocates for the continued collective effort in perinatal medicine to employ principles of nanomedicine to improve maternal and fetal care. Nanomedicine may be able to increase the safety and efficacy of a drug by manipulating physical and chemical properties of the particles (such as size and surface chemistry) to vector it preferentially to the affected tissue, minimizing fetal exposure and combating risks associated with systemic drug toxicities to the mother and the developing fetus. Such targeted delivery of drugs to the maternal organs could revolutionize the treatment of high-risk patients for conditions such as growth abnormalities and preterm labor.